Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SKYE
stocks logo

SKYE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.307
+5.31%
--
--
-0.342
+22.14%
--
--
-0.268
-40%
Estimates Revision
The market is revising No Change the revenue expectations for Skye Bioscience, Inc. (SKYE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -69.75%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-69.75%
In Past 3 Month
Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 9.80 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 9.80 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.210
sliders
Low
2.00
Averages
9.80
High
20.00
Current: 1.210
sliders
Low
2.00
Averages
9.80
High
20.00
H.C. Wainwright
Ananda Ghosh
Buy
initiated
$20
2025-09-30
Reason
H.C. Wainwright
Ananda Ghosh
Price Target
$20
2025-09-30
initiated
Buy
Reason
H.C. Wainwright analyst Ananda Ghosh initiated coverage of Skye Bioscience with a Buy rating and $20 price target. The firm believes the company's nimacimab can introduce a new mechanism of longstanding interest to obesity clinicians. Nimacimab is a peripherally restricted monoclonal antibody targeting the CB1 receptor, designed to deliver the metabolic benefits of CB1 blockade without the psychiatric side effects that derailed earlier small molecule antagonists, the analyst tells investors in a research note. H.C. Wainwright views Sykes shares as undervalued at current levels.
Evercore ISI
Michael DiFiore
Outperform
initiated
$10
2025-08-14
Reason
Evercore ISI
Michael DiFiore
Price Target
$10
2025-08-14
initiated
Outperform
Reason
Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience with an Outperform rating and $10 price target.
Evercore ISI
Outperform
initiated
$10
2025-08-14
Reason
Evercore ISI
Price Target
$10
2025-08-14
initiated
Outperform
Reason
As previously reported, Evercore ISI initiated coverage of Skye Bioscience with an Outperform rating and $10 price target. Nimacimab is the "only weekly SC large molecule CB1 inhibitor in development," says the analyst, who sees the drug having the potential to "fill critical gaps in obesity care." The 26-week Phase 2a readout due in late Q3 or early Q4 will be "the next major test," the analyst added.
Oppenheimer
Oppenheimer
Outperform
to
Perform
downgrade
$21 -> $17
2025-05-12
Reason
Oppenheimer
Oppenheimer
Price Target
$21 -> $17
2025-05-12
downgrade
Outperform
to
Perform
Reason
Oppenheimer lowered the firm's price target on Skye Bioscience to $17 from $21 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 results with $11.8M OpEx and $59.2M cash providing expected runway through Q1 2027 and supporting execution of Phase 2a CBeyond and manufacturing for Phase 2b. Oppenheimer looks forward to top-line data for CBeyond in late-Q3/early-Q4, as Skye previously announced that ahead-of-schedule enrollment would eliminate the need for an interim analysis. Regarding CBeyond trial extension, it sees longer-term dosing and follow-up as potentially derisking for nimacimab ahead of a dose-ranging Phase 2b.
Citizens Capital Markets
Jonathan Wolleben
Buy
Reiterates
$15
2025-03-21
Reason
Citizens Capital Markets
Jonathan Wolleben
Price Target
$15
2025-03-21
Reiterates
Buy
Reason
Craig-Hallum
Albert Lowe
Strong Buy
Maintains
$18 → $14
2025-03-21
Reason
Craig-Hallum
Albert Lowe
Price Target
$18 → $14
2025-03-21
Maintains
Strong Buy
Reason
Craig-Hallum analyst Albert Lowe lowered the firm's price target on Skye Bioscience to $14 from $18 and keeps a Buy rating on the shares. The firm notes that due to enrollment of the ongoing Phase II study of nimacimab in obesity completing ahead of schedule, the company is removing the previously planned Q2 2025 interim analysis in favor of moving up the topline readout to September/October, from Q4 2025 previously. While this change makes the first look at the obesity data slightly later, the topline dataset for this important catalyst will be more robust, containing 26-week data on all 136 patients, Craig-Hallum adds. The benchmark for success will be an 8% weight loss with Albert focused on improvements in GI tolerability and lean mass preservation relative to GLP1 therapies. In addition, an open-label extension was added to increase the treatment time to 52 weeks, giving nimacimab sufficient time to show its full weight loss potential in future updates.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Skye Bioscience Inc (SKYE.O) is -1.02, compared to its 5-year average forward P/E of -2.30. For a more detailed relative valuation and DCF analysis to assess Skye Bioscience Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.30
Current PE
-1.02
Overvalued PE
1.29
Undervalued PE
-5.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SKYE News & Events

Events Timeline

(ET)
2025-11-10
16:11:39
Skye Bioscience Announces Q3 EPS of 32c, Matching Consensus Estimate
select
2025-11-05 (ET)
2025-11-05
07:45:13
Skye Bioscience to unveil key findings from CBeyond study on nimacimab
select
2025-09-19 (ET)
2025-09-19
07:03:01
Skye Bioscience Reveals Phase 1b Results from Nimacimab Research
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
05:22 AMGlobenewswire
Skye Bioscience Faces Class Action for Alleged Securities Fraud, Investors May Claim Losses
  • Lawsuit Notification: Levi & Korsinsky LLP has informed investors of Skye Bioscience, Inc. about a class action lawsuit for alleged securities fraud covering the period from November 4, 2024, to October 3, 2025, aimed at recovering losses for affected investors.
  • False Statements Allegation: The complaint alleges that the defendants made false statements regarding the efficacy of the company's lead product candidate, nimacimab, overstating its clinical, regulatory, and commercial prospects, which misled investors.
  • Claim Deadline: Investors who suffered losses must request to be appointed as lead plaintiff by January 16, 2026, to participate in any recovery, with no out-of-pocket costs required for participation.
  • Legal Team Expertise: Levi & Korsinsky has over 20 years of experience in securities litigation, securing hundreds of millions for aggrieved shareholders, showcasing their expertise and successful track record in complex cases.
[object Object]
Preview
7.0
00:41 AMPRnewswire
Skye Biosciences Faces Class Action Lawsuit Over Misleading Statements
  • Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential securities fraud claims against Skye Biosciences, particularly regarding the overstated efficacy of its drug nimacimab, which may have led to significant investor losses.
  • Stock Price Plunge: Following the release of disappointing clinical trial results on October 6, 2025, Skye's stock price plummeted by 60%, from $4.75 to $1.90, indicating a severe loss of market confidence in the company's prospects.
  • Class Action Deadline: Investors must apply by January 16, 2026, to serve as lead plaintiffs in the class action lawsuit, highlighting the urgency of legal action for affected shareholders.
  • Insufficient Disclosure: The lawsuit alleges that Skye and its executives failed to disclose the true clinical prospects of nimacimab, potentially misleading investors in their decision-making, which could adversely affect the company's future financing and market trust.
[object Object]
Preview
7.0
12-04Globenewswire
Skye Bioscience Shares Plunge 60%, Prompting Class Action Lawsuit
  • Stock Price Plunge: On October 6, 2025, Skye Bioscience's stock fell by 60% to close at $1.90 per share after the company announced that its nimacimab study failed to meet primary weight loss endpoints, significantly impacting investor confidence and triggering a class action lawsuit.
  • Legal Action: Investors are required to file a lead plaintiff motion by January 16, 2026, indicating a strong response to potential corporate wrongdoing, which could expose the company to greater legal risks and liabilities.
  • Investor Rights Protection: The Portnoy Law Firm offers complimentary case evaluations for affected investors, aiming to assist them in recovering losses due to corporate missteps, highlighting the necessity of legal services in such situations.
  • Historical Recovery: The firm's founding partner has recovered over $5.5 billion for investors in similar cases, demonstrating a successful track record that may enhance investor trust in their services and encourage participation in the lawsuit.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Skye Bioscience Inc (SKYE) stock price today?

The current price of SKYE is 1.21 USD — it has decreased -0.82 % in the last trading day.

arrow icon

What is Skye Bioscience Inc (SKYE)'s business?

Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

arrow icon

What is the price predicton of SKYE Stock?

Wall Street analysts forecast SKYE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKYE is 9.80 USD with a low forecast of 2.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Skye Bioscience Inc (SKYE)'s revenue for the last quarter?

Skye Bioscience Inc revenue for the last quarter amounts to -13.26M USD, increased 39.30 % YoY.

arrow icon

What is Skye Bioscience Inc (SKYE)'s earnings per share (EPS) for the last quarter?

Skye Bioscience Inc. EPS for the last quarter amounts to -13364375.00 USD, increased 97.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for Skye Bioscience Inc (SKYE)'s fundamentals?

The market is revising No Change the revenue expectations for Skye Bioscience, Inc. (SKYE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -69.75%.
arrow icon

How many employees does Skye Bioscience Inc (SKYE). have?

Skye Bioscience Inc (SKYE) has 11 emplpoyees as of December 05 2025.

arrow icon

What is Skye Bioscience Inc (SKYE) market cap?

Today SKYE has the market capitalization of 38.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free